Vildagliptin Treatment on the Portal Venous Pressure and Hepatosteatosis in Patients with Type 2 Diabetes Mellitus

Basit Öğe Kaydı
dc.authoridYolbaş, Servet/0000-0001-8516-9769
dc.authorwosidaydin, sinem/ABI-4185-2020
dc.authorwosidOzkan, Tuba/D-4490-2019
dc.authorwosidYolbaş, Servet/ABI-5312-2020
dc.contributor.authorKaratoprak, Cumali
dc.contributor.authorKilicarslan, Rukiye
dc.contributor.authorCakirca, Mustafa
dc.contributor.authorAydin, Sinem
dc.contributor.authorOzkan, Tuba
dc.contributor.authorKocaman, Orhan
dc.contributor.authorYolbas, Servet
dc.date.accessioned2024-08-04T21:02:23Z
dc.date.available2024-08-04T21:02:23Z
dc.date.issued2018
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjective: This study investigated how vildagliptin (a di-peptidyl peptidase 4 inhibitor) affects portal vein pressure and hepatosteatosis in patients with type 2 diabetes mellitus. Methods: This cross-sectional study evaluated the use of specific drugs for at least 3 months on two groups of type 2 diabetes mellitus cases. Group 1 used metformin and gliclazide, Group 2 used the same amounts of metformin and gliclazide, with the addition of vildagliptin. Using Doppler ultrasound, all cases were measured for portal vein flow velocity, portal vein flow and portal vein diameter. Degree of hepatosteatosis was also recorded. Results: A total of 97 patients completed the study. The study finished with 49 type 2 DM patients in Group1 (20 men, 29 women) and 48 patients in Group2 (20 men, 28 women. No significant difference was found in term of age, gender, BMI, HbA1c, mean arterial pressure, LDL-C, HDL-C or triglyceride levels in two groups. Portal vein flow velocity, portal vein flow volume, and portal vein diameter of all cases were measured by Doppler ultrasound in both groups. No significant difference was found between the groups (respectively p=0.92,p=0.60, p=0.92). There was no significant difference between groups regarding to ultrasonographic grading of hepatosteatosis Conclusion: Treating type 2 diabetes mellitus patients with vildagliptin for had no effect on portal vein hemodynamics and hepatosteatosis as assessed with Doppler ultrasound. Further long-term studies with better evaluation methods are needed to demonstrate any expected beneficial effect of vildagliptin on portal hemodynamics and hepatosteatosis.en_US
dc.identifier.doi10.14235/bs.2018.1050
dc.identifier.endpage5en_US
dc.identifier.issn2148-2373
dc.identifier.issue1en_US
dc.identifier.startpage1en_US
dc.identifier.urihttps://doi.org/10.14235/bs.2018.1050
dc.identifier.urihttps://hdl.handle.net/11616/104710
dc.identifier.volume6en_US
dc.identifier.wosWOS:000436137800002en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherAvesen_US
dc.relation.ispartofBezmialem Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDi-Peptidyl peptidase 4 inhibitorsen_US
dc.subjectvildagliptinen_US
dc.subjectportal vein pressureen_US
dc.subjecthepatosteatosisen_US
dc.subjecttype 2 diabetes mellitusen_US
dc.titleVildagliptin Treatment on the Portal Venous Pressure and Hepatosteatosis in Patients with Type 2 Diabetes Mellitusen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu